The first man to receive a genetically modified kidney transplant from a pig has been discharged from hospital, writes BBC.

The 62-year-old was sent home on Wednesday, two weeks after the ground-breaking surgery at Massachusetts General Hospital (MGH).

Organ transplants from genetically modified pigs have failed in the past. But the success of this procedure so far has been hailed by scientists as a historic milestone in the field of transplantation. The news was shared in a press release on Wednesday by MGH, which is Harvard Medical School’s largest teaching hospital in the US city of Boston. In the release, the hospital said the patient, Richard “Rick” Slayman of Weymouth, Massachusetts, had been battling end-stage kidney disease and required an organ transplant.

His doctors successfully transplanted a genetically-edited pig kidney into his body over a four-hour-long surgery on 16 March. They said Mr Slayman’s kidney is now functioning well and he is no longer on dialysis. In a statement, Mr Slayman said being able to leave hospital and go home was “one of the happiest moments” of his life: “I’m excited to resume spending time with my family, friends, and loved ones free from the burden of dialysis that has affected my quality of life for many years”.

In 2018, he had a human kidney transplant from a deceased donor, however it began to fail last year, and doctors raised the idea of a pig kidney transplant: “I saw it not only as a way to help me, but a way to provide hope for the thousands of people who need a transplant to survive”.

The new pig kidney he received was modified by Cambridge-based pharmaceutical company eGenesis to remove “harmful pig genes and add certain human genes to improve its compatibility with humans|, it said.

For the procedure, the hospital said it drew from its history as being behind the world’s first successful human organ transplant - a kidney - in 1954, as well as research it had conducted with eGenesis on xenotransplantation (interspecies organ transplants) over the past five years. The procedure was greenlit by the Food and Drug Administration, who offered a single Expanded Access Protocol - also known as compassionate use - that is used for patients with life-threatening illnesses to grant them access to experimental treatment.